Pharmacology, Institute of Basic Science, Universidade Federal do Rio Grande, Rio Grande, Brazil.
Microbiology, Department of Microbiology, Immunology, and Parasitology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Am J Physiol Endocrinol Metab. 2024 Jul 1;327(1):E89-E102. doi: 10.1152/ajpendo.00054.2024. Epub 2024 May 29.
The gut microbiome, a complex assembly of microorganisms, significantly impacts human health by influencing nutrient absorption, the immune system, and disease response. These microorganisms form a dynamic ecosystem that is critical to maintaining overall well-being. Prebiotics and probiotics are pivotal in regulating gut microbiota composition. Prebiotics nourish beneficial bacteria and promote their growth, whereas probiotics help maintain balance within the microbiome. This intricate balance extends to several aspects of health, including maintaining the integrity of the gut barrier, regulating immune responses, and producing metabolites crucial for metabolic health. Dysbiosis, or an imbalance in the gut microbiota, has been linked to metabolic disorders such as type 2 diabetes, obesity, and cardiovascular disease. Impaired gut barrier function, endotoxemia, and low-grade inflammation are associated with toll-like receptors influencing proinflammatory pathways. Short-chain fatty acids derived from microbial fermentation modulate anti-inflammatory and immune system pathways. Prebiotics positively influence gut microbiota, whereas probiotics, especially and strains, may improve metabolic outcomes, such as glycemic control in diabetes. It is important to consider strain-specific effects and study variability when interpreting these findings, highlighting the need for further research to optimize their therapeutic potential. The aim of this report is therefore to review the role of the gut microbiota in metabolic health and disease and the effects of prebiotics and probiotics on the gut microbiome and their therapeutic role, integrating a broad understanding of physiological mechanisms with a clinical perspective.
肠道微生物群是由多种微生物组成的复杂集合体,通过影响营养吸收、免疫系统和疾病反应对人类健康产生重大影响。这些微生物形成了一个动态的生态系统,对维持整体健康至关重要。益生元和益生菌是调节肠道微生物群组成的关键因素。益生元滋养有益细菌并促进其生长,而益生菌有助于维持微生物群的平衡。这种复杂的平衡延伸到健康的几个方面,包括维持肠道屏障的完整性、调节免疫反应和产生对代谢健康至关重要的代谢物。肠道微生物群失调或失衡与代谢紊乱有关,如 2 型糖尿病、肥胖症和心血管疾病。肠道屏障功能受损、内毒素血症和低度炎症与影响促炎途径的 toll 样受体有关。微生物发酵产生的短链脂肪酸调节抗炎和免疫系统途径。益生元对肠道微生物群有积极影响,而益生菌,特别是 和 菌株,可能改善代谢结果,如糖尿病的血糖控制。在解释这些发现时,需要考虑到菌株特异性效应和研究变异性,这突出表明需要进一步研究以优化其治疗潜力。因此,本报告的目的是综述肠道微生物群在代谢健康和疾病中的作用,以及益生元和益生菌对肠道微生物群的影响及其治疗作用,将生理机制的广泛理解与临床观点相结合。